1. Search Result
Search Result
Results for "

strychnine

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

1

Screening Libraries

2

Natural
Products

1

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-W014504

    Endogenous Metabolite Metabolic Disease
    DL-Kynurenine is a key metabolite in the tryptophan metabolic pathway and can cross the blood-brain barrier. DL-Kynurenine has a bidirectional regulatory effect on neural excitability. DL-Kynurenine can enhance the convulsive and lethal effects caused by strychnine. DL-Kynurenine is the precursor of Kynurenic acid (HY-100806), which is an antagonist at the glycine site of NMDA receptors and can counteract excitatory toxins. DL-Kynurenine can be used for research on neurotoxicity .
    DL-Kynurenine
  • HY-101620
    MRZ 2-514
    1 Publications Verification

    iGluR Neurological Disease
    MRZ 2-514 is an antagonist of the strychnine-insensitive modulatory site of the NMDA receptor (glycineB), with Ki of 33 μM.
    MRZ 2-514
  • HY-E70012

    Bacterial Infection Neurological Disease
    Penicillinase is an enzyme capable of hydrolyzing penicillin. Penicillinase converts penicillin into penicilloic acid, which has no antigenicity, and destroys the antibacterial, antigenic and epileptogenic properties of penicillin. Penicillinase shortens the duration of penicillin-induced seizures and neutralizes the ability of penicillin to form epileptogenic foci. Penicillinase can be used in research related to penicillin hypersensitivity and penicillin-induced encephalopathy .
    Penicillinase
  • HY-W681659

    KB-509

    GABA Receptor Neurological Disease
    Flutoprazepam (KB-509), a benzodiazepine drug, possesses anticonflict effect. Flutoprazepam (KB-509) prevents maximal electroshock, pentetrazol, and strychnine-induced convulsions in mice .
    Flutoprazepam
  • HY-19545

    R-(+)-SCH-23390

    Dopamine Receptor Neurological Disease
    SCH-23390 is a dopamine D1-like receptor antagonist (with Ki values of 0.2 nM and 0.3 nM for the D1 and D5 receptor subtypes, respectively). SCH-23390 can shorten the latency period for cocaine-induced lever pressing behavior in rats. SCH-23390 can also eliminate generalized seizures caused by chemical convulsants, such as arecoline (HY-B0726A) and strychnine, and is used in research on neurological disorders related to the dopamine system .
    SCH-23390
  • HY-W014504S1

    Isotope-Labeled Compounds Endogenous Metabolite Metabolic Disease
    DL-Kynurenine-d7 is the deuterium labeled DL-Kynurenine. DL-Kynurenine is a key metabolite in the tryptophan metabolic pathway and can cross the blood-brain barrier. DL-Kynurenine has a bidirectional regulatory effect on neural excitability. DL-Kynurenine can enhance the convulsive and lethal effects caused by strychnine. DL-Kynurenine is the precursor of Kynurenic acid (HY-100806), which is an antagonist at the glycine site of NMDA receptors and can counteract excitatory toxins. DL-Kynurenine can be used for research on neurotoxicity.
    DL-Kynurenine-d7
  • HY-121670

    Others Neurological Disease
    Ambenoxan is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
    Ambenoxan
  • HY-121670A

    Adrenergic Receptor Neurological Disease
    Ambenoxan hydrochloride is a central nervous system-acting skeletal muscle relaxant that is effective in mice, rats, rabbits, dogs, and monkeys without loss of the righting reflex. It has no peripheral neuromuscular blocking effects and significantly reduces or eliminates decerebrate rigidity in rabbits, but does not antagonize the effects of strychnine, leptazol, or tremorine. Like other central nervous system depressants, ambenoxan prolongs sleep duration with hexobarbitone, but it has no local anesthetic effects. In anesthetized cats, the agent lowers blood pressure and reduces the pressor response to epinephrine, but has no effect on norepinephrine.
    Ambenoxan hydrochloride
  • HY-W014504R

    Reference Standards Endogenous Metabolite Metabolic Disease
    DL-Kynurenine (Standard) is the analytical standard of DL-Kynurenine. This product is intended for research and analytical applications. DL-Kynurenine is a key metabolite in the tryptophan metabolic pathway and can cross the blood-brain barrier. DL-Kynurenine has a bidirectional regulatory effect on neural excitability. DL-Kynurenine can enhance the convulsive and lethal effects caused by strychnine. DL-Kynurenine is the precursor of Kynurenic acid (HY-100806), which is an antagonist at the glycine site of NMDA receptors and can counteract excitatory toxins. DL-Kynurenine can be used for research on neurotoxicity.
    DL-Kynurenine (Standard)
  • HY-182479

    iGluR Others Neurological Disease
    MDL 100748 is an NMDA receptor glycine site antagonist. MDL 100748 modulates NMDA receptor function by acting at the strychnine-insensitive glycine site, which is required for NMDA receptor activation alongside glutamate. MDL 100748 decreases response rates in operant conditioning sessions in phencyclidin (PCP)-trained rats. MDL 100748 can be used for reserach on dementias and schizophrenia .
    MDL 100748
  • HY-W975902

    Glycine Receptor (GlyR) Neurological Disease
    MDL-27531 acts functionally like a glycine agonist. MDL-27531 selectively reduces hindlimb contractions. MDL-27531 selectively reverses strychnine-induced seizures in mice. MDL-27531 inhibits pentylenetetrazol-induced seizures with an ED50 of 55 mg/kg. MDL-27531 promotes the binding of benzodiazepine antagonist Ro 15-1788 to cerebral cortex of mice without changing GABA levels. MDL-27531 can be studied in research on reflex control dysfunction .
    MDL-27531

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

 

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

 

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: